Healthcare provider Zydus Cadila has signed a sub-licensing agreement with the Medicines Patent Pool (MPP) centring on the generic production of Daklinza (daclatasvir).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Zydus Cadila, MPP, Bristol-Myers Squibb, Daklinza